Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856700 | 0.86 | GSK3B (0.43) | ROCK2ROCK1NPC1RAB9ATAS1R3 | |
| SCHEMBL14348317 | 0.85 | GSK3B (0.45) | ROCK2ROCK1NPC1RAB9AGSK3B | |
| SCHEMBL4854577 | 0.82 | GSK3B (0.49) | ROCK2ROCK1NPC1RAB9AGSK3B | |
| SCHEMBL5229604 | 0.82 | SPR (0.47) | ROCK2ROCK1NPC1RAB9ATAS1R3 | |
| SCHEMBL5232508 | 0.80 | MAPK8 (0.55) | ROCK2GSK3B | |
| Trifluoroacetic Acid SCHEMBL5668175 | 0.80 | GSK3B (0.42) | ROCK2ROCK1NPC1RAB9AGSK3B | |
| SCHEMBL5233935 | 0.79 | ROCK2 (0.40) | ROCK2RAB9AGSK3BALDH1A1 | |
| SCHEMBL5233639 | 0.78 | GSK3B (0.52) | ROCK2ROCK1GSK3BALDH1A1MAPK1 | |
| SCHEMBL5236116 | 0.78 | GSK3B (0.52) | ROCK2ROCK1GSK3BALDH1A1MAPK1 | |
| SCHEMBL4848283 | 0.77 | GSK3B (0.51) | ROCK2ROCK1GSK3BALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | ROCK2 4122/4885ROCK1 4428/4885NPC1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.